Cargando…

Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors

Pleural effusion is a rare immune-related adverse event for lung cancer patients receiving immune checkpoint inhibitors (ICIs). We enrolled 281 lung cancer patients treated with ICIs and 17 were analyzed. We categorized the formation of pleural effusion into 3 patterns: type 1, rapid and massive; ty...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Po-Hsin, Yang, Tsung-Ying, Chen, Kun-Chieh, Huang, Yen-Hsiang, Tseng, Jeng-Sen, Hsu, Kuo-Hsuan, Wu, Yu-Chen, Liu, Ko-Jiunn, Chang, Gee-Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087817/ https://www.ncbi.nlm.nih.gov/pubmed/33931705 http://dx.doi.org/10.1038/s41598-021-89043-4

Ejemplares similares

Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment
por: Lee, Po-Hsin, et al.
Publicado: (2022)

The long-term outcomes of cirrhotic patients with pleural effusion
por: Hung, Tsung-Hsing, et al.
Publicado: (2018)

ANA positivity and complement level in pleural fluid are potential diagnostic markers in discriminating lupus pleuritis from pleural effusion of other aetiologies
por: Chen, Der-Yuan, et al.
Publicado: (2021)

Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant)
por: Wu, Jia-Jun, et al.
Publicado: (2022)

Pleural sarcoidosis diagnosed on the basis of an increased CD4/CD8 lymphocyte ratio in pleural effusion fluid: a case report
por: Kumagai, Toru, et al.
Publicado: (2015)

Clinical value of CD97 and CD55 levels in the differential diagnosis of tuberculous and malignant pleural effusions
por: Wang, Chunyan, et al.
Publicado: (2021)

Novel biomarker analysis of pleural effusion enhances differentiation of tuberculous from malignant pleural effusion
por: Chen, Kuan-Yuan, et al.
Publicado: (2016)

Analysis of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON biomarkers in exudative lymphocyte-dominant pleural effusion
por: Mehraban, Zahra, et al.
Publicado: (2022)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Defect in recruiting effector memory CD8(+) T-cells in malignant pleural effusions compared to normal pleural fluid
por: Scherpereel, Arnaud, et al.
Publicado: (2013)

Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion
por: Takeuchi, Eiji, et al.
Publicado: (2021)

Determination of Interleukin 27-Producing CD4(+) and CD8(+) T Cells for The Differentiation Between Tuberculous and Malignant Pleural Effusions
por: Liu, Ya-Lan, et al.
Publicado: (2016)

Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma
por: Augeri, Stefania, et al.
Publicado: (2018)

An unusual cause of pleural effusion
por: Shih, Chi‐Wei, et al.
Publicado: (2021)

Pleural Effusion
por: Gray, Frank D.
Publicado: (1963)

Pleural Effusion
por: Brunton, T. Lauder
Publicado: (1898)

Pleural Effusion
por: Sherding, Robert G., et al.
Publicado: (2006)

Pleural Effusions
Publicado: (1877)

Acute myeloid leukemia with leukemic pleural effusion and high levels of pleural adenosine deaminase: A case report and review of literature
por: Wang, Sing-Ting, et al.
Publicado: (2021)

Evaluation of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease
por: Sánchez-Otero, Nuria, et al.
Publicado: (2014)

Spontaneous Hemorrhagic Pericardial and Pleural Effusion in a Patient Receiving Apixaban
por: Cinelli, Michael, et al.
Publicado: (2019)

Anaphylatoxins orchestrate Th17 response via interactions between CD16(+) monocytes and pleural mesothelial cells in tuberculous pleural effusion
por: Deng, Shuanglinzi, et al.
Publicado: (2021)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

Characteristics of Malignant Pleural Effusion Resident CD8(+) T Cells from a Heterogeneous Collection of Tumors
por: Dhupar, Rajeev, et al.
Publicado: (2020)

Clinical value of haptoglobin and soluble CD163 testing for the differential diagnosis of tuberculous and malignant pleural effusions
por: Gao, Jinying, et al.
Publicado: (2019)

Tissue-Resident Memory-Like CD8(+) T Cells Exhibit Heterogeneous Characteristics in Tuberculous Pleural Effusion
por: Yu, Sifei, et al.
Publicado: (2021)

GC‐MS metabolomics identifies novel biomarkers to distinguish tuberculosis pleural effusion from malignant pleural effusion
por: Liu, Yongxia, et al.
Publicado: (2021)

Filarial pleural effusion
por: Gowrinath, K.
Publicado: (2011)

Tuberculous Pleural Effusion
por: Schlesinger, Shira A., et al.
Publicado: (2012)

Filariasis and pleural effusion
por: Wiwanitkit, Somsri, et al.
Publicado: (2013)

Encysted Pleural Effusions
por: Viswanathan, R.
Publicado: (1946)

Cholesterol Pleural Effusion
por: Curran, Thomas M.
Publicado: (1948)

Fœtid Pleural Effusion
por: James, Alexander
Publicado: (1891)

The Treatment of Pleural Effusion
Publicado: (1893)

Cytodiagnosis of Pleural Effusions
por: Gulland, G. Lovell
Publicado: (1902)

Fœtid Pleural Effusion
por: James, Alexander
Publicado: (1891)

The sandwiched pleural effusion
por: Venkatnarayan, Kavitha, et al.
Publicado: (2019)

Myelomatous pleural effusion
por: Escribano Serrat, Silvia, et al.
Publicado: (2022)

Soluble CD40 in plasma and malignant pleural effusion with non-small cell lung cancer: A potential marker of prognosis
por: Mu, Chuan-Yong, et al.
Publicado: (2015)

Recurrent, late-onset pleural effusions in elderly patients receiving pacemaker therapy
por: Xiong, Mengqing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9m4uqc57sqfj2mn1gc92sv5cp0